Advertisement
Screener

Karyopharm Therapeutics Inc. (KPTI) Accumulated Other Comprehensive Income

2.8 / 5 stars · 68/120 Roast Me

Karyopharm Therapeutics Inc. Accumulated Other Comprehensive Income

Karyopharm Therapeutics Inc. (KPTI) had Accumulated Other Comprehensive Income of $41.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-13.

Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent

us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-13

  • 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $41.00K.
  • 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $43.00K.
  • 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $71.00K.
  • 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$259.00K.
Period endAccumulated Other Comprehensive Income (Loss), Net of Tax
2026-06-30$41.00K
10-Q · filed 2026-08-13
2026-03-31$43.00K
10-Q · filed 2026-05-14
2025-12-31$71.00K
10-Q · filed 2026-08-13
2025-09-30-$259.00K
10-Q · filed 2025-11-03
2025-06-30-$251.00K
10-Q · filed 2025-08-11
2025-03-31-$321.00K
10-Q · filed 2025-05-12
2024-12-31-$356.00K
10-K · filed 2026-02-13
2024-09-30-$222.00K
10-Q · filed 2024-11-05
2024-06-30-$605.00K
10-Q · filed 2024-08-06
2024-03-31-$518.00K
10-Q · filed 2024-05-08
2023-12-31-$161.00K
10-K · filed 2025-02-19
2023-09-30-$742.00K
10-Q · filed 2023-11-02
2023-06-30-$783.00K
10-Q · filed 2023-08-02
2023-03-31-$419.00K
10-Q · filed 2023-05-04
2022-12-31-$638.00K
10-K · filed 2024-02-29
2022-09-30-$752.00K
10-Q · filed 2022-11-03
2022-06-30-$538.00K
10-Q · filed 2022-08-04
2022-03-31$87.00K
10-Q · filed 2022-05-05
2021-12-31$191.00K
10-K · filed 2023-02-17
2021-09-30$372.00K
10-Q · filed 2021-11-03
2021-06-30$196.00K
10-Q · filed 2021-08-05
2021-03-31$301.00K
10-Q · filed 2021-05-04
2020-12-31$518.00K
10-K · filed 2022-03-01
2020-09-30$603.00K
10-Q · filed 2020-11-02
2020-06-30$891.00K
10-Q · filed 2020-08-04
2020-03-31-$420.00K
10-Q · filed 2020-05-05
2019-12-31-$37.00K
10-K · filed 2021-02-24
2019-09-30-$30.00K
10-Q · filed 2019-11-04
2019-06-30$61.00K
10-Q · filed 2019-08-07
2019-03-31-$28.00K
10-Q · filed 2019-05-09
2018-12-31-$244.00K
10-K · filed 2020-02-26
2018-09-30-$153.00K
10-Q · filed 2018-11-08
2018-06-30-$260.00K
10-Q · filed 2018-08-07
2018-03-31-$286.00K
10-Q · filed 2018-05-10
2017-12-31-$217.00K
10-K · filed 2019-02-28
2017-09-30-$90.00K
10-Q · filed 2017-11-02
2017-06-30-$165.00K
10-Q · filed 2017-08-08
2017-03-31-$204.00K
10-Q · filed 2017-05-04
2016-12-31-$274.00K
10-K · filed 2018-03-15
2016-09-30-$28.00K
10-Q · filed 2016-11-07
2016-06-30$138.00K
10-Q · filed 2016-08-04
2016-03-31$94.00K
10-Q · filed 2016-05-09
2015-12-31-$282.00K
10-K · filed 2017-03-16
2015-09-30-$26.00K
10-Q · filed 2015-11-09
2015-06-30-$143.00K
10-Q · filed 2015-08-10
2015-03-31$19.00K
10-Q · filed 2015-05-11
2014-12-31-$29.00K
10-K · filed 2016-03-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
Edesa Biotech, Inc. (EDSA)Canada$0.039B
Incannex Healthcare Inc. (IXHL)$0.040B-22.32
CervoMed Inc. (CRVO)United States$0.038B-1.39
Celularity Inc (CELU)United States$0.038B-0.34
Actinium Pharmaceuticals, Inc. (ATNM)United States$0.038B2.73
FILANA THERAPEUTICS, INC. (FLNA)United States$0.038B-1.05
Kairos Pharma, LTD. (KAPA)United States$0.041B
PMGC Holdings Inc. (ELAB)United States$0.037B
BriaCell Therapeutics Corp. (BCTX)$0.037B
Seres Therapeutics, Inc. (MCRB)United States$0.036B-3.45